Research programme: rheumatoid arthritis gene therapies - Biogen IdecAlternative Names: Rheumatoid arthritis gene therapies research programme - Biogen Idec
Latest Information Update: 24 Feb 2011
At a glance
- Originator Biogen Idec
- Class Gene therapies
- Mechanism of Action Cytokine inhibitors; Interleukin 1 receptor agonists
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- Discontinued Rheumatoid arthritis
Most Recent Events
- 29 Oct 2004 Preclinical trials in Rheumatoid arthritis in Netherlands (Intra-articular)
- 29 Oct 2004 Preclinical trials in Rheumatoid arthritis in USA (Intra-articular)